<DOC>
	<DOCNO>NCT00021918</DOCNO>
	<brief_summary>To examine independent association serum total homocysteine C-reactive protein arteriosclerotic cardiovascular disease morbidity mortality .</brief_summary>
	<brief_title>Serum Total Homocysteine C-Reactive Protein - Ancillary IDNT</brief_title>
	<detailed_description>BACKGROUND : Patients diabetic nephropathy experience markedly increase rate morbidity mortality due arteriosclerotic cardiovascular disease [ CVD ] . Established arteriosclerotic risk factor age , sex , cigarette smoking , hypertension , dyslipidemia account adequately excess CVD risk . Prospective data general population , much limited finding diabetic cohort . cohort chronic renal disease , link elevated level total homocysteine ( tHcy ) C-reactive protein ( CRP ) arteriosclerotic CVD morbidity mortality . Determination baseline serum total homocysteine C-reactive protein concentration Irbesartan Type 2 Diabetic Nephropathy Trial ( IDNT ) cohort affords truly unique opportunity evaluate potential independent relationship putative CVD risk factor subsequent CVD morbidity mortality , patient population . The IDNT multicenter , randomize , double-blind , placebo-controlled trial 1,715 hypertensive , Type 2 diabetic patient age 30 70 overt nephropathy ( 24 hour urinary protein excretion great 900 mg serum creatinine 90 265 micromols/L ) . The IDNT compare effect angiotensin II receptor antagonist irbesartan placebo amlodipine progression renal disease mortality . The IDNT support Bristol-Myers Squibb Company Princeton , New Jersey Sanofi-Synthelabo Paris , France . The study response initiative `` Ancillary Studies Heart , Lung , Blood Disease Trials '' release National Heart , Lung , Blood Institute June 2000 . DESIGN NARRATIVE : The first specific aim conduct longitudinal analyse potential `` Independent '' relationship baseline concentration serum total homocysteine C-reactive protein full IDNT cohort , subsequent : pool cardiovascular disease morbidity mortality ( primary analysis ) . total mortality , ( multivariable -adjustment establish predictor cardiovascular disease morbidity/ mortality , total mortality ) . The second specific aim conduct cross-sectional analysis assess baseline serum total homocysteine C-reactive protein concentration full IDNT cohort , relation potential baseline determinant analytes , include : B-vitamin status ; age gender ; renal function index , i.e . creatinine-based glomerular filtration rate estimate , proteinuria ; index glycemia , prevalent cardiovascular disease ( CVD ) , traditional CVD risk factor ( i.e. , particular , smoking , blood pressure , total cholesterol/HDL cholesterol ratio ) . The study completion date list record obtain `` End Date '' enter Protocol Registration Results System ( PRS ) record .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>No eligibility criterion</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2005</verification_date>
</DOC>